The broad purpose of this program-project is to show that advances AAV-based gene therapy enable stable, long-term suppression of HIV-1 replication. Our immediate goal is to stably suppress an ongoing SHIV-infection in rhesus macaques, using specific combinations of antiviral proteins delivered by self-complementary AAV vectors. Any effective therapy for HIV-1 infection has to solve the problem of viral escape. This project addresses the problem of viral escape from a cocktail of antibodies iteratively, by rapidly identifying viral escape pathways and adjusting these cocktails so that these pathways are blocked. We are aided in this effort by a variant of CD4-lg, fused to a 14-amino-acid peptide that closely mimics a high-affinity binding region of CCR5. This enhanced CD4-lg (""""""""eCD4-lg"""""""") neutralizes as efficiently as the best neutralizing antibodies and binds only necessarily conserved regions of gp120. Thus escape from eCD4-lg is more difficult, and may coincide with a decrease viral fitness. We therefore first determine which anfi-gp120 CD4- and CCR5-binding site antibodies best complement escape from eCD4-lg. To do so, we develop libraries of SHIV proviruses diversified in their env genes. Using several such libraries, we select in parallel a number of envelope glycoproteins resistant to eCD4-lg. We determine which antibodies best neutralize these resistant variants, and generate two antibody cocktails which we hypothesize will best suppress in vivo viral escape. We then evaluate these cocktails in vivo, using self-complementary AAV (scAAV) vectors to deliver scFv-Fc forms of these antibodies to SHIV infected macaques. Envelope glycoproteins from viruses that escape In vivo will be cloned, characterized, and used to select by phage display new variants of already broadly neutralizing antibodies. These antibody variants can either replace or complement the original antibody in a cocktail. We then repeat the process to develop new antibody cocktails and again characterize their efficacy in macaques. This project will: (1) determine whether and under what circumstances viral escape can be suppressed, (2) generate broader and more potent forms of already exceptional HIV-1 neutralizing antibodies, and (3) identify a set of scAAV-deliverable inhibitors that may suppress HIV-1 replication in humans.
Adeno-associated virus (AAV) vectors expressing HIV-1 neutralizing antibodies have the potential to replace current anti-retroviral combination therapies. However, the problem of viral escape from these protein inhibitors must be solved before AAV expressed transgenes can be useful therapeutically. In this project we address this critical problem of viral escape, and improve several HIV-1 neutralizing antibodies.
|Wang, Dan; Li, Jia; Song, Chun-Qing et al. (2018) Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. Nat Biotechnol 36:839-842|
|Fetzer, Ina; Gardner, Matthew R; Davis-Gardner, Meredith E et al. (2018) eCD4-Ig Variants That More Potently Neutralize HIV-1. J Virol 92:|
|Yoon, Yeonsoo; Wang, Dan; Tai, Phillip W L et al. (2018) Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses. Nat Commun 9:412|
|Zhang, Wei; Li, Linjing; Su, Qin et al. (2018) Gene Therapy Using a miniCEP290 Fragment Delays Photoreceptor Degeneration in a Mouse Model of Leber Congenital Amaurosis. Hum Gene Ther 29:42-50|
|Tai, Phillip W L; Xie, Jun; Fong, Kaiyuen et al. (2018) Adeno-associated Virus Genome Population Sequencing Achieves Full Vector Genome Resolution and Reveals Human-Vector Chimeras. Mol Ther Methods Clin Dev 9:130-141|
|Mou, Huihui; Zhong, Guocai; Gardner, Matthew R et al. (2018) Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence. Mol Ther 26:1277-1286|
|Wang, Dan; Gao, Guangping (2018) Taking a Hint from Structural Biology: To Better Understand AAV Transport across the BBB. Mol Ther 26:336-338|
|Wang, Dan; Li, Jia; Tran, Karen et al. (2018) Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space. Hum Gene Ther Methods 29:75-85|
|Wang, Dan; Li, Shaoyong; Gessler, Dominic J et al. (2018) A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. Mol Ther Methods Clin Dev 9:234-246|
|Lu, Yi; Tai, Phillip W L; Ai, Jianzhong et al. (2018) Transcriptome Profiling of Neovascularized Corneas Reveals miR-204 as a Multi-target Biotherapy Deliverable by rAAVs. Mol Ther Nucleic Acids 10:349-360|
Showing the most recent 10 out of 46 publications